Semaglutide-linked sight loss highlights systemic gaps in drug safety monitoring and patient equity
Original framing: “Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds” — The Guardian - World
Scientific evidence suggests that semaglutide may affect vascular systems, potentially leading to optic nerve complications. However, current studies are limited in duration and diversity, making it difficult to generalize findings across populations.
The systemic gaps in drug safety monitoring revealed by the semaglutide-related sight loss incident are rooted in a combination of corporate influence on regulatory bodies, underrepresentation of marginalized groups in clinical trials, and a lack of integration of traditional knowledge.
Historical precedents like the thalidomide crisis show that these gaps can lead to widespread harm. By enhancing post-market surveillance, diversifying clinical trials, and incorporating holistic health perspectives, we can create a more equitable and responsive healthcare system. This approach not only addresses the immediate risks of semaglutide but also builds a foundation for safer, more inclusive medical practices in the future.